Comments on: bluebird bio Presents Long-Term Efficacy and Safety Data from Clinical Studies of LentiGlobin® Gene Therapy for Transfusion-Dependent β-Thalassemia (TDT) at 24th European Hematology Association (EHA) Congress

Comments on: bluebird bio Presents Long-Term Efficacy and Safety Data from Clinical Studies of LentiGlobin® Gene Therapy for Transfusion-Dependent β-Thalassemia (TDT) at 24th European Hematology Association (EHA) Congress https://www.novumpr.nl/2019/06/14/bluebird-bio-presents-long-term-efficacy-and-safety-data-from-clinical-studies-of-lentiglobin-gene-therapy-for-transfusion-dependent-%ce%b2-thalassemia-tdt-at-24th-european-hematology-associat/?utm_source=rss&utm_medium=rss&utm_campaign=bluebird-bio-presents-long-term-efficacy-and-safety-data-from-clinical-studies-of-lentiglobin-gene-therapy-for-transfusion-dependent-%25ce%25b2-thalassemia-tdt-at-24th-european-hematology-associat NovumPR press releases Fri, 14 Jun 2019 10:25:49 +0000 hourly 1 https://wordpress.org/?v=6.8.3